同济大学学报(医学版)2024,Vol.45Issue(3) :447-453.DOI:10.12289/j.issn.2097-4345.23401

特发性肺纤维化合并肺癌研究进展

Research progress of idiopathic pulmonary fibrosis complicated with lung cancer

王静一 赵萌萌 张苑
同济大学学报(医学版)2024,Vol.45Issue(3) :447-453.DOI:10.12289/j.issn.2097-4345.23401

特发性肺纤维化合并肺癌研究进展

Research progress of idiopathic pulmonary fibrosis complicated with lung cancer

王静一 1赵萌萌 2张苑2
扫码查看

作者信息

  • 1. 同济大学医学院,上海 200092
  • 2. 同济大学附属肺科医院呼吸与危重症医学科,上海 200433
  • 折叠

摘要

特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)合并肺癌(lung cancer,LC)的发病率近年明显升高,IPF不仅是肺癌发生的独立危险因素,且二者存在部分重叠的风险因素与分子靶点,但具体致病机制尚未阐明.IPF-LC临床诊治仍面临困境,部分患者病理诊断困难,而部分抗肿瘤治疗可能导致IPF的急性加重,各种因素叠加导致总体IPF-LC预后较差.因此,探索新诊断方法与制定合适的治疗方案相当必要.本文针对IPF-LC流行病学、可能的致病机制及诊疗难点进行综述.

Abstract

The incidence of idiopathic pulmonary fibrosis complicated with lung cancer(IPF-LC)has been rising,however,the pathogenic mechanism of IPF-LC is not clear.IPF is an independent risk factor for lung cancer,while there are partially overlapped risk factors and common molecular targets for these two conditions.It is facing difficulties to diagnose and treat IPF-LC,and even some anti-tumor treatments may lead to acute exacerbations of IPF and even death of patients,which makes a poor prognosis of IPF-LC patients.Therefore,it is necessary to explore new diagnostic methods and develop appropriate treatment plans for IPF-LC.This article reviews the epidemiology,pathogenesis and difficulties in diagnosis and treatment of IPF-LC.

关键词

特发性肺纤维化/肺癌/致病机制/研究进展

Key words

idiopathic pulmonary fibrosis/lung cancer/pathogenic mechanism/research progress

引用本文复制引用

基金项目

国家自然科学基金面上项目(82270064)

国家自然科学基金青年项目(82100073)

出版年

2024
同济大学学报(医学版)
同济大学

同济大学学报(医学版)

CSTPCD
影响因子:0.51
ISSN:1008-0392
段落导航相关论文